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f late an increasing number of publications
about glucagon, a hormone that once enjoyed
center stage with insulin but for several de-
cades has been sitting in the wings, have
appeared. The primary function of this islet -cell
product is to regulate hepatic glycogenolysis to supply
increased endogenous glucose production. Clinically,
this is a critical role. Release of this hormone is
triggered by hypoglycemia, and it rescues patients with
type 2 diabetes from hypoglycemia when too much
insulin is used for glycemic control. Sadly, patients with
type 1 diabetes do not have this luxury. In the absence
of functional -cells, the -cell does not respond to
hypoglycemia. The central relationship between these
two cells is that the -cell, by its own response to stop
secreting insulin during hypoglycemia, provides an es-
sential signal to the -cell to release glucagon. This
chain reaction only happens during hypoglycemia, so it
takes both signals (hypoglycemia and an insulin decre-
ment) to activate the -cell. This phenomenon has been
variably termed the intraislet insulin hypothesis (1) or
the insulin switch-off signal (2).
A major stimulus for refocusing on glucagon has been
an increasing number of intriguing studies from basic
electrophysiological, biochemical, and animal physiology
laboratories involving other regulators of -cell function,
including zinc, GABA, glutamate, somatostatin, ghrelin,
and the autonomic nervous system (rev. in 3 and reference
list of 1). These studies cause consideration of the concept
of synergistic activation of the -cell by forces other than
low glucose and insulin levels. This general line of thinking
is reasonable because we have long appreciated that the
human body is replete with redundant regulation of its
many important functions. Stimulated by the potential role
of zinc as a regulator, Cooperberg and Cryer (4) set out to
evaluate their hypothesis that “an increase in insulin per
se, i.e., in the absence of zinc, suppresses glucagon secre-
tion during euglycemia and that a decrease in insulin per
se stimulates glucagon secretion during hypoglycemia in
humans,” as reported in this issue of Diabetes. One of the
recent zinc studies was our own (5) in which glucagon
secretion in rodents was suppressed by zinc and stimu-
lated by a combination of hypoglycemia plus the switch off
of a zinc or insulin infusion that had been started before
hypoglycemia was induced. We later suggested that the
mechanism whereby zinc exerts inﬂuence over -cells
involves the SUR1 subunit of ATP-sensitive K
 (KATP)
channels (6) (Fig. 1). The surprise in these experiments
was that an infusion containing zinc-free insulin was not
successful in suppressing glucagon, and switch-off of
zinc-free insulin was not successful in stimulating gluca-
gon secretion during hypoglycemia. Yet, this same prepa-
ration of zinc-free insulin was active in providing the
anticipated insulin effect of increasing glucose uptake by
L6 muscle and HepG23 hepatic cell lines (5). This led to
our hypothesis that it is zinc bound to insulin within native
-cells, which dissociates (because of higher pH of blood)
from the extruded insulin granules in islet portal blood to
travel downsteam to -cells, that is the active principle
suppressing glucagon secretion, not the insulin molecule
itself. On the other hand, Cooperberg and Cryer have now
demonstrated that systemic intravenous infusion of a
zinc-free insulin preparation in type 1 diabetic humans
suppressed glucagon levels and that switching off the
zinc-free insulin infusion during hypoglycemia activated
glucagon secretion. These data clearly conﬁrmed their
hypothesis.
An essential consideration is whether conﬁrmation of a
hypothesis using one paradigm necessarily disproves an
antithetical hypothesis using another paradigm. Would
that science were so simple! A comparison of the two
studies (4,5) turns up obvious differences (rats vs. humans,
anesthesia vs. no anesthesia, and systemic vs. retrograde
intrapancreatic venous infusions). There are other more
complex methodological problems, such as absence of
conﬁrmation that the zinc-free insulin infused intrave-
nously in the antecubital vein of humans was still zinc-free
by the time it underwent circulation in zinc-containing
blood and through zinc-containing tissues before it
reached the pancreatic artery and -cells. Another consid-
eration is that regulation of -cells in this human study
might have been due to effects of the zinc-free insulin
infusion on the central nervous system, which is known to
directly regulate glucagon secretion (3). What is left unex-
plained by the human studies is why zinc-free insulin was
ineffective in the animal studies. Clearly, the infusion
technique via the pancreatic artery that we used in the
animal studies, which provided intimate contact between
the infusate of zinc-free insulin and -cells, cannot be used
in humans. So, as often happens when comparing animal
studies and human studies, more work and deeper thought
must be expended before the two data sets can be
reconciled. Put another way, scientists who respect and
believe each others’ data not infrequently disbelieve their
hypotheses—which certainly keeps us busy and hard at
work . . . a good thing in general, and speciﬁcally a good
thing for the current resurgence of interest in glucagon
research.
But, in closing, one might ask, “Who cares?” Of what
value is raising new basic questions in physiology or any
From the Paciﬁc Northwest Diabetes Research Institute, Seattle,Washington.
Corresponding author: R. Paul Robertson, rpr@pnri.org.
DOI: 10.2337/db10-1238
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
See accompanying original article, p. 2936.
COMMENTARY
diabetes.diabetesjournals.org DIABETES, VOL. 59, NOVEMBER 2010 2735branch of science when a pragmatic clinical fact is, after
all, a fact pure and simple. Insulin suppresses glucagon.
Benjamin Franklin is reputed to have made a quip in which
he defended scientiﬁc inquiry with a gentle smile and an
alternative question, “Of what possible value is a newborn
infant?”
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FIG. 1. Regulation of glucagon secretion by zinc. Left panel: -cell
electrical and hormonal status in states of physiological and elevated
glucose conditions. -cells release zinc and insulin hexamers into the
intraislet periportal circulation. Zinc dissociates from insulin and
reaches downstream -cells where it binds to and opens the KATP
channels. K
 ions leave the cell and hyperpolarize the -cell, thus
preventing voltage-dependent calcium channels from opening. Gluca-
gon granules are not mobilized and remain stored inside the cell. Right
panel: When blood glucose levels decrease in response to exogenous
insulin, -cell insulin and zinc secretion decrease as well. KATP chan-
nels on -cells close, K
 remains in the cell, and the -cell depolarizes,
which induces calcium channels to open, and calcium enters the cell.
Intracellular calcium rises, which induces glucagon exocytotic granules
to migrate to the plasma membrane where they fuse and release glucagon
into the portal venous system. (Reproduced from Slucca et al. [6]).
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